|
1
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: From highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tallman MS, Andersen JW, Schiffer CA,
Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd
L, Willman C, et al: All-trans retinoic acid in acute promyelocytic
leukemia: Long-term outcome and prognostic factor analysis from the
North American Intergroup protocol. Blood. 100:4298–4302. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Asou N, Kishimoto Y, Kiyoi H, Okada M,
Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Kobayashi
T, et al: Japan Adult Leukemia Study Group: A randomized study with
or without intensified maintenance chemotherapy in patients with
acute promyelocytic leukemia who have become negative for
PML-RARalpha transcript after consolidation therapy: The Japan
Adult Leukemia Study Group (JALSG) APL97 study. Blood. 110:59–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adès L, Guerci A, Raffoux E, Sanz M,
Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S,
et al: European APL Group: Very long-term outcome of acute
promyelocytic leukemia after treatment with all-trans retinoic acid
and chemotherapy: The European APL Group experience. Blood.
115:1690–1696. 2010. View Article : Google Scholar
|
|
5
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Gruppo Italiano Malattie Ematologiche dell'Adulto;
German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance
Leukemia: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ratnaike RN: Acute and chronic arsenic
toxicity. Postgrad Med J. 79:391–396. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mandlekar S and Kong ANT: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Avgeropoulos NG and Batchelor TT: New
treatment strategies for malignant gliomas. Oncologist. 4:209–224.
1999.PubMed/NCBI
|
|
9
|
Niitsu N, Ishii Y, Matsuda A and Honma Y:
Induction of differentiation of acute promyelocytic leukemia cells
by a cytidine deaminase-resistant analogue of
1-β-D-arabinofuranosylcytosine,
1-(2-deoxy-2-methylene-β-D-erythro-pentofuranosyl)cytidine. Cancer
Res. 61:178–185. 2001.PubMed/NCBI
|
|
10
|
Takahashi T, Kawakami K, Mishima S,
Akimoto M, Takenaga K, Suzumiya J and Honma Y: Cyclopamine induces
eosinophilic differentiation and upregulates CD44 expression in
myeloid leukemia cells. Leuk Res. 35:638–645. 2011. View Article : Google Scholar
|
|
11
|
Miyake T, Honma Y, Urano T, Kato N and
Suzumiya J: Combined treatment with tamoxifen and a fusicoccin
derivative (ISIR-042) to overcome resistance to therapy and to
enhance the antitumor activity of 5-fluorouracil and gemcitabine in
pancreatic cancer cells. Int J Oncol. 47:315–324. 2015.PubMed/NCBI
|
|
12
|
Honma Y: Cotylenin A - a plant growth
regulator as a differentiation-inducing agent against myeloid
leukemia. Leuk Lymphoma. 43:1169–1178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yen A, Roberson MS, Varvayanis S and Lee
AT: Retinoic acid induced mitogen-activated protein
(MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent
MAP kinase activation needed to elicit HL-60 cell differentiation
and growth arrest. Cancer Res. 58:3163–3172. 1998.PubMed/NCBI
|
|
14
|
Wang X and Studzinski GP: Activation of
extracellular signal-regulated kinases (ERKs) defines the first
phase of 1,25-dihydroxyvitamin D3-induced
differentiation of HL60 cells. J Cell Biochem. 80:471–482. 2001.
View Article : Google Scholar
|
|
15
|
Dudley DT, Pang L, Decker SJ, Bridges AJ
and Saltiel AR: A synthetic inhibitor of the mitogen-activated
protein kinase cascade. Proc Natl Acad Sci USA. 92:7686–7689. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ishii Y, Kiyota H, Sakai S and Honma Y:
Induction of differentiation of human myeloid leukemia cells by
jasmonates, plant hormones. Leukemia. 18:1413–1419. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nazarewicz RR, Zenebe WJ, Parihar A,
Larson SK, Alidema E, Choi J and Ghafourifar P: Tamoxifen induces
oxidative stress and mitochondrial apoptosis via stimulating
mitochondrial nitric oxide synthase. Cancer Res. 67:1282–1290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kauss MA, Reiterer G, Bunaciu RP and Yen
A: Human myeloblastic leukemia cells (HL-60) express a membrane
receptor for estrogen that signals and modulates retinoic
acid-induced cell differentiation. Exp Cell Res. 314:2999–3006.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berman E, McBride M, Lin S, Menedez-Botet
C and Tong W: Phase I trial of high-dose tamoxifen as a modulator
of drug resistance in combination with daunorubicin in patients
with relapsed or refractory acute leukemia. Leukemia. 9:1631–1637.
1995.PubMed/NCBI
|
